NEW YORK – Fulgent Genetics has already recouped its investments in COVID-19 testing, according to company officials, which should help grow full-year 2020 revenues fourfold, compared to 2019.
"Our COVID-19 business has surpassed our most augmented expectations," CEO Ming Hsieh said Tuesday on a conference call with investors.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
